Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB9QSJ)

• Drug Name: CRx-191 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psoriatic disorder	EA90	Discontinued in Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMB9QSJ

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[3]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[4]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[5]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[6]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[7]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[8]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[9]
Etanercept	DMCV109	Arthritis	FA20	Approved	[10]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[11]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[12]

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[13]
Fumaric acid	DMP83UZ	Multiple sclerosis	8A40	Phase 3	[14]
VIR-201	DMAMIU4	Human immunodeficiency virus infection	1C62	Phase 1/2	[15]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[16]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[17]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[18]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[19]
TG-1042	DMS4BUK	B-cell lymphoma	2A86	Discontinued in Phase 2	[20]
VPM-4-001	DMZHAVG	Prostate cancer	2C82.0	Preclinical	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Inhibitor	[2]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025635)
• [2] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [3] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [4] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [5] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [6] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [7] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [8] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [9] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [10] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [11] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [12] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
• [15] EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
• [16] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [17] Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
• [18] T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
• [19] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [20] Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
• [21] BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.